David M. Berman - 17 Feb 2025 Form 4 Insider Report for Immunocore Holdings plc (IMCR)

Role
HEAD OF R&D
Signature
/s/ Lily Hepworth, Attorney-in-Fact
Issuer symbol
IMCR
Transactions as of
17 Feb 2025
Transactions value $
$0
Form type
4
Filing time
19 Feb 2025, 16:18:07 UTC
Previous filing
01 Mar 2024
Next filing
12 Sep 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMCR Employee Share Option (Right to Buy) Award $0 +130K $0.00 130K 17 Feb 2025 Ordinary Shares 130K $29.60 Direct F1
transaction IMCR Restricted Share Units Award $0 +47.3K $0.00 47.3K 17 Feb 2025 Ordinary Shares 47.3K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option award shall vest on February 17, 2026, and 6.25% of the shares subject to the option award shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.
F2 Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share.
F3 The RSUs vest in four equal annual installments beginning February 17, 2026, subject to the Reporting Person's continuous service through each such vesting date.